Glucose-dependent action of glucagon-like peptide-1(7-37) in vivo during short- or long-term administration
- 30 September 1995
- journal article
- Published by Elsevier in Metabolism
- Vol. 44 (9) , 1231-1237
- https://doi.org/10.1016/0026-0495(95)90021-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.Journal of Clinical Investigation, 1994
- Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humansDiabetes, 1994
- Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrationsJournal of Clinical Endocrinology & Metabolism, 1993
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993
- Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic SubjectsDiabetes Care, 1992
- Effects of truncated glucagon-like peptide-1 on the responses of starved sheep to glucoseJournal of Endocrinology, 1991
- GLP-1 and GLP-17-36 AmidePancreas, 1991
- Effect of Glucagon-Like Peptide-1 on Gastric Somatostatin and Gastrin Secretion in the RatScandinavian Journal of Gastroenterology, 1990
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANPublished by Elsevier ,1987